- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
BRCA2 Associated With Risk of Lung Cancer Among Smokers
BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.
BRCA2
The gene is known to increase risk for breast and ovarian cancers.
Genetic bad actor has been implicated in yet another cancer.
BRCA2
Now, as a new genomic study shows, a rare variant of the gene is associated with increased risk for squamous cell lung cancer, particularly among cigarette smokers.
"This variant confers one the strongest associations found to date for cancer among those identified by genome-wide association studies and identifies a subset of people who are particularly susceptible to harm associated with smoking," said Christopher Amos, PhD, director of the Center for Genomic Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire.
Nature Genetics.
Dr. Amos is senior author of a meta-analysis combining data from 4 genome-wide association studies (GWAS) involving more than 11,000 people with lung cancer. The results were published online June 1 in
Read the report here: http://bit.ly/1l3vktn
Source: Medscape
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
